Yazar "Karaca, I." seçeneğine göre listele

Listeleniyor 1 - 4 / 4
  • Küçük Resim Yok
    Öğe
    DIGITAL BORSUK-ULAM THEOREM
    (Iranian Mathematical Soc, 2017) Burak, G.; Karaca, I.
    The aim of this paper is to compute a simplicial cohomology group of some specific digital images. Then we define ring and algebra structures of a digital cohomology with the cup product. Finally, we prove a special case of the Borsuk-Ulam theorem for digital images.
  • Küçük Resim Yok
    Öğe
    Fixed point theorems and an Application in Parametric Metric Spaces
    (Inst Math & Mechanics Azerbaijan, 2017) Ege, O.; Karaca, I.
    In this paper, we give concepts of coupled fixed and coupled coincidence point in parametric metric spaces. We also prove a coupled fixed point theorem in this space and give a corollary and an example about the main result. Finally, we give an application to homotopy with proof.
  • Küçük Resim Yok
    Öğe
    Oncomir miR17, Tumour Suppressor miR146a, miR302d, and Oncogene miR19B Expressions in Hepatoblastoma Patients
    (Wiley-Blackwell, 2016) Ecevit, C. O.; Aktas, S.; Yildirim, H. T.; Demirag, B.; Erbay, A.; Karaca, I.; Celik, A.; Demir, B.; Ercetin, P.; Olgun, N.
  • Küçük Resim Yok
    Öğe
    Pharmacological agents in development for diabetic macular edema
    (BioMed Central Ltd, 2020) Sadiq, M.A.; Halim, M.S.; Hassan, M.; Onghanseng, N.; Karaca, I.; Agarwal, A.; Nguyen, Q.D.
    Background: Diabetic macular edema (DME) is the leading cause of visual loss in patients with diabetic retinopathy. There has been a paradigm shift in the treatment of DME since the advent of anti-vascular endothelial growth factor (anti-VEGF) therapy. The safety and efficacy of anti-VEGF therapy has been well established. Although efficacious, currently approved anti-VEGF agents are associated with certain limitations, which include, among others: frequent need for injections, high treatment cost and variable response to treatment. These challenges have led to an active search for more novel agents that may be able to overcome these limitations. Areas covered: The index review focuses on novel treatment agents that target various pathways in patients with DME. These agents are used either as monotherapy or in combination with other agents in the management of DME. Drugs discussed include novel anti-VEGF inhibitors, TIE-2 receptor modulators, integrin peptide inhibitors, rho kinase inhibitors, and future therapies such as neuroprotection and gene therapy. Conclusions: The future of investigational pharmacological therapy appears promising for patients with DME. Results from early clinical trials indicate that newer agents highlighted in the study may be safe and efficacious treatment options for patients with DME. However, data from large multicenter clinical trials need to be analyzed before these agents can be incorporated into clinical practice. © 2020 The Author(s).